Search
Neurogene Inc
NGNEAdd to Watchlist
29.820USD
-1.450-4.64%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
471.21MMarket Cap
LossP/E TTM
More Details of Neurogene Inc Company
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Neurogene Inc Info
Ticker SymbolNGNE
Company nameNeurogene Inc
IPO dateMar 07, 2014
CEOMcMinn (Rachel L)
Number of employees107
Security typeOrdinary Share
Fiscal year-endMar 07
Address535 W 24Th Street
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10011
Phone18772375020
Websitehttps://www.neurogene.com/
Ticker SymbolNGNE
IPO dateMar 07, 2014
CEOMcMinn (Rachel L)
Company Executives of Neurogene Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
10.11K
-67.26%
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
1.97K
-106.49%
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Dr. Rachel L. McMinn, Ph.D.
Dr. Rachel L. McMinn, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Christine Mikail Cvijic, J.D.
Ms. Christine Mikail Cvijic, J.D.
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Dr. Robert A. Baffi
Dr. Robert A. Baffi
Independent Director
Independent Director
--
--
Dr. Cory Freedland
Dr. Cory Freedland
Independent Director
Independent Director
--
--
Mr. Robert Keith Woods
Mr. Robert Keith Woods
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
10.11K
-67.26%
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
1.97K
-106.49%
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Dr. Rachel L. McMinn, Ph.D.
Dr. Rachel L. McMinn, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Christine Mikail Cvijic, J.D.
Ms. Christine Mikail Cvijic, J.D.
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Revenue Breakdown
FY2025
FY2025Q4
FY2025Q3
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
10.87%
Redmile Group, LLC
9.24%
RTW Investments L.P.
8.62%
McMinn (Rachel L.)
8.24%
Casdin Capital, LLC
8.20%
Other
54.83%
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
10.87%
Redmile Group, LLC
9.24%
RTW Investments L.P.
8.62%
McMinn (Rachel L.)
8.24%
Casdin Capital, LLC
8.20%
Other
54.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
39.55%
Hedge Fund
26.47%
Investment Advisor
18.98%
Venture Capital
12.24%
Research Firm
9.42%
Individual Investor
8.94%
Sovereign Wealth Fund
2.35%
Bank and Trust
0.10%
Pension Fund
0.06%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
225
17.70M
113.37%
-1.04M
2025Q4
214
16.75M
108.11%
-2.07M
2025Q3
202
15.71M
110.06%
-3.24M
2025Q2
207
17.85M
125.13%
-2.21M
2025Q1
216
18.11M
126.54%
-1.93M
2024Q4
211
17.68M
118.99%
+934.89K
2024Q3
193
15.29M
117.57%
+50.95K
2024Q2
185
14.71M
113.65%
+656.15K
2024Q1
190
13.87M
122.85%
+4.51M
2023Q4
186
10.89M
99.88%
+9.09M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Samsara BioCapital, LLC
1.72M
11.03%
--
--
Dec 31, 2025
Redmile Group, LLC
1.46M
9.37%
+160.58K
+12.36%
Dec 31, 2025
RTW Investments L.P.
1.36M
8.75%
--
--
Dec 31, 2025
McMinn (Rachel L.)
1.27M
8.17%
-3.35K
-0.26%
Mar 26, 2026
Casdin Capital, LLC
1.30M
8.32%
--
--
Dec 31, 2025
EcoR1 Capital, LLC
1.27M
8.16%
--
--
Dec 31, 2025
Baker Bros. Advisors LP
991.69K
6.37%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
825.00K
5.3%
+31.54K
+3.97%
Dec 31, 2025
Trails Edge Capital Partners LP
785.00K
5.04%
+785.00K
--
Dec 31, 2025
TD Securities, Inc.
681.34K
4.37%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
iShares Neuroscience and Healthcare ETF
0.42%
Franklin Genomic Advancements ETF
0.21%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.14%
iShares Neuroscience and Healthcare ETF
Proportion0.42%
Franklin Genomic Advancements ETF
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
Fidelity Enhanced Small Cap ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
iShares Biotechnology ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
Date
Ex-dividend Date
Type
Ratio
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
